Search

Your search keyword '"Inga Möller"' showing total 2 results
Start Over Author "Inga Möller" Journal european journal of cancer (oxford, england : 1990)
2 results on '"Inga Möller"'

1. Clinical and genetic analysis of melanomas arising in acral sites

Author

Eva Hadaschik, Ioana Cosgarea, Cindy Franklin, Antje Sucker, Philipp Jansen, Alexander Roesch, Titus J. Brinker, Klaus G. Griewank, Rajmohan Murali, Annette Paschen, Lisa Zimmer, Anne Zaremba, Inga Möller, Selma Ugurel, Dirk Schadendorf, and Elisabeth Livingstone

Subjects
0301 basic medicine, Neuroblastoma RAS viral oncogene homolog, Oncology, Adult, Male, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Immune checkpoint inhibitors, medicine.medical_treatment, Medizin, Tert promoter, Genetic analysis, Article, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, medicine, Humans, In patient, Genetic Testing, skin and connective tissue diseases, Promoter Regions, Genetic, neoplasms, Melanoma, Telomerase, Aged, Aged, 80 and over, Chemotherapy, business.industry, High-Throughput Nucleotide Sequencing, Extremities, Middle Aged, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, Cohort, Mutation, Female, business
Abstract

Study aim Melanomas arising in acral sites are associated with a poorer prognosis than other melanoma subtypes. The aim of this study was to evaluate clinical-pathological and genetic characteristics as well as therapeutic responses of a larger cohort of patients with melanomas arising in acral sites. Methods Clinical data of 134 patients with melanomas arising in acral sites from the Dept. of Dermatology Essen were collected and analysed with regard to clinicopathological characteristics and treatment responses. Genetic analysis with targeted next-generation sequencing was done on 50 samples. Results In our cohort, BRAF (30%), NRAS (28%), TERT promoter (26%), NF1 (14%) and KIT (6%) were frequently identified mutations. Comparing tumours situated on palms and soles with melanomas arising on dorsal acral sites, a higher frequency of NRAS (39.1% versus 25%) and NF1 (17.3% versus 0%) and lower frequencies of BRAF (21.7% versus 75%) and TERT promoter (8.6% versus 50%) mutations were observed. MAPK activating mutations were identified in 64% of tumours. Overall survival was longer in patients treated with immune checkpoint inhibitors as first-line treatment than in patients receiving other systemic therapies (i.e. BRAF/MEK inhibitors and chemotherapy). Conclusion Our data suggest that the genetics of melanomas arising in acral sites varies by tumour location and may influence biological behaviour.

Published
2019

2. Oncogene status as a diagnostic tool in ocular and cutaneous melanoma

Author

Uwe Hillen, Lisa Zimmer, Dirk Schadendorf, Cindy Franklin, Inga Möller, Antje Sucker, Elisabeth Livingstone, Claudia H D Metz, Henning Reis, Klaus-Peter Steuhl, Simone L. Scholz, Klaus G. Griewank, Bastian Schilling, Henrike Westekemper, and Ioana Cosgarea

Subjects
Neuroblastoma RAS viral oncogene homolog, Male, Uveal Neoplasms, Cancer Research, Pathology, medicine.medical_specialty, Skin Neoplasms, Medizin, Uveal Neoplasm, Metastasis, 03 medical and health sciences, 0302 clinical medicine, Medicine, Humans, 030212 general & internal medicine, Stage (cooking), Melanoma, Aged, GNA11, business.industry, Oncogenes, Middle Aged, medicine.disease, Dermatology, Oncology, 030220 oncology & carcinogenesis, Cutaneous melanoma, Mutation, Neoplasms, Unknown Primary, Female, business, GNAQ
Abstract

The majority of human tumours can be easily and correctly diagnosed based on clinical information and pathological assessment. In some cases however, correct diagnosis can prove difficult. In such cases, molecular approaches can be of significant diagnostic value. In recent years, the understanding of genetic alterations has greatly increased. In cutaneous melanoma, it is now well recognised, that 70-80% of tumours harbour BRAF and NRAS mutations. These mutations never occur in uveal melanoma. On the other hand activating GNAQ and GNA11 mutations are found in ∼90% of uveal melanomas, and are exceptionally rare in other melanomas (

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results